

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted for Form 1449A/PTO

**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/559,925
Filing Date	May 2, 2006
First Named Inventor	Oron YACOBY-ZEEVI et al
Art Unit	1644
Examiner Name	DIBRINO, MARIANNE NMN
Attorney Docket Number	30337

Sheet	1	of	2
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov/patents/otherdocs/kinds.htm](http://www.uspto.gov/patents/otherdocs/kinds.htm).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

<sup>4</sup> For the purpose of this form, the indication of the year of the issue of the European Patent Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached

Transmittal of information is required by 37 CFR 1.912(a)(2). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application for a patent. Transmittal is covered by 35 U.S.C. 198 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed transmittal form to the USPTO. Time will vary depending upon the individual case. Any comments on this collection or the time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/559,925
Filing Date	May 2, 2006
First Named Inventor	Oron YACOBY-ZEEVI et al
Group Art Unit	1644
Examiner Name	DIBRINO, MARIANNE NMN
Attorney Docket Number	30337

Sheet 2 of 2

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/M.D./	6	Agrawal "Antisense Therapeutics: Is It as Simple as Complementary Base Recognition", Molecular Medicine Today, 6: 72-81, 2002.	
	7	Branch "A Good Antisense Molecule Is Hard to Find", Trends in Biochemical Sciences, 23(2): 45-50, 1998. Abstract.	
	8	InSight "Monoclonal Anti-Human Heparanase 1 (HPA1) Antibody Clone HP130", InSight Biopharmaceuticals Ltd., 2 P., 2008.	
	9	InSight "Monoclonal Anti-Human Heparanase 1 (HPA1) Antibody Clone HP3/17", InSight Biopharmaceuticals Ltd., 2 P., 2008.	
	10	Kuyvenhoven et al. "Assessment of Serum Matrix Metalloproteinases MMP-2 and MMP-9 After Human Liver Transplantation: Increased Serum MMP-9 Level in Acute Rejection", Transplantation, 77(11): 1646-1652, 2004. Abstract.	
	11	Nakajima "Heparanases and Tumor Metastasis", Tanpakushitsu Kakusan Koso, 37(11): 1753-1758, 1992. Abstract.	
	12	Pontremoli et al. "Changes in Activity of Fructose-1,6-Bisphosphate Aldolase in Livers of Fasted Rabbits and Accumulation of Crossreacting Immune Material", Proc. Natl. Acad. Sci. USA, 76(12): 6323-6325, 1979.	
	13	Quax et al. "Metastatic Behavior of Human Melanoma Cell Lines in Nude Mice Correlates With Urokinase-Type Plasminogen Activator, Its Type-1 Inhibitor, and Urokinase-Mediated Matrix Degradation", The Journal of Cell Biology, 115(1): 191-199, 1991.	
	14	Savion et al. "Murine Macrophage Heparanase: Inhibition and Comparison With Metastatic Tumor Cells", Journal of Cellular Physiology, 130: 77-84, 1987.	
/M.D./	15	Sordat et al. "Modulation of the Malignant Phenotype With the Urokinase-Type Plasminogen Activator and the Type I Plasminogen Activator Inhibitor", Cell Differentiation and Development, 32: 277-286, 1990.	

Examiner Signature	/Marianne DiBrino/	Date Considered	01/08/2009
--------------------	--------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2